             NYTimes.com no longer supports Internet Explorer 9 or earlier. Please upgrade your browser.  LEARN MORE »           Sections   Home   Search  Skip to content  Skip to navigation  View mobile version      The New York Times       Business Day | Factbox-Who Are Hong Kong's Top Biotech IPO Hopefuls?          Search   Subscribe Now  Log In  0  Settings      Close search   Site Search Navigation     Search NYTimes.com     Clear this text input     Go        https://nyti.ms/2Fs06Jr      Loading...      See next articles       See previous articles           Site Navigation    Site Mobile Navigation       Advertisement          Supported by     Business Day   Factbox-Who Are Hong Kong's Top Biotech IPO Hopefuls?   By REUTERS APRIL 29, 2018, 7:40 P.M. E.D.T.     Continue reading the main story  Share This Page   Continue reading the main story           HONG KONG —  Biotechs without revenue can apply to list in Hong Kong from Monday under new rules aimed at attracting listings, mostly from China's fast-developing market. The move is part of a bold effort to rival New York's Nasdaq, the biggest and best-known finance hub for biotech companies. Companies (in alphabetical order) that have already shown interest in testing the Hong Kong market include: Ascentage Pharma Founded in 2010, Ascentage focuses on therapeutics for cancers, hepatitis B and aging-related diseases. It has built a pipeline of seven products in clinical development and 17 in total approved for clinical studies in China, the United States and Australia. The firm counts the state-backed SDIC Fund Management and U.S. Oriza Ventures among its investors and aims to raise up to $300 million.   Advertisement   Continue reading the main story   Ascletis Hangzhou-based Ascletis develops therapies for viral diseases, cancer, and fatty liver diseases. Its pipeline includes four clinical stage drug candidates, one drug candidate ready to apply for IND (investigational new drug) approval and two preclinical drug candidates.  Continue reading the main story         Advertisement   Continue reading the main story       Current investors include Goldman Sachs, the healthcare fund C-bridge Capital and the QianHai fund of funds. It is planning to raise about $500 million, IFR, a Thomson Reuters publication,  reported. Grail California-based Grail is a cancer-detection start-up and will release its first product this year, a screening test for nasopharyngeal cancer - a cancer of the part of the throat behind the nose. Investors in Grail include Jeff Bezos, Bill Gates and Tencent. The firm is planning to raise up to $500 million, according to IFR. Hua Medicine Set up in 2011, Hua Medicine is a diabetes-focused drug developer with a novel treatment in a phase 3 clinical trial that it expects to be approved in China by 2019. Hua's investors include the U.S. venture capital firms ARCH Venture Partners and Venrock. It is planning to raise at least $400 million.  Newsletter Sign Up  Continue reading the main story        Please verify you're not a robot by clicking the box.  Invalid email address. Please re-enter.  You must select a newsletter to subscribe to.     Sign Up         You agree to receive occasional updates and special offers for The New York Times's products and services.       Thank you for subscribing.  An error has occurred. Please try again later.  You are already subscribed to this email.  View all New York Times newsletters.    See Sample  Manage Email Preferences  Not you?  Privacy Policy  Opt out or contact us anytime      Innovent Biologics Founded in 2011, Innovent makes biologics to treat cancer, eye disorders, auto-immune disorders, and cardiovascular diseases. The company has a portfolio of 16 potential drugs to treat cancer and other diseases, and has seven in clinical development. It has also partnered with Eli Lilly to co-develop three cancer treatments in China and overseas. Fidelity Investment and Temasek are among its shareholders, and it is looking to raise between $300 million and $500 million, sources said.   Advertisement   Continue reading the main story   Shanghai Henlius Biotech Set up in 2009, Henlius develops new drugs and biosimilars - generic versions of biologics, which are made from living cells - for cancer and autoimmune diseases such as lymphoma. Backed by the Chinese conglomerate Fosun International, Henlius has no marketed products yet but has four biosimilar products and three innovative drugs in various clinical stages. It is planning an IPO that could raise at least $500 million, sources said. Shanghai Tasly Pharmaceutical Founded in 2001, Shanghai Tasly is the biopharma arm of Tasly Pharmaceutical Group, which is best known for traditional Chinese medicines. In 2012, Shanghai Tasly launched a drug aimed at treating blood clot-induced heart attacks, known as pro-UK, in China. It is also developing more than 10 other drugs. The company is looking to raise about $1 billion, in what is likely to be the largest biotech float this year. (Reporting by Julie Zhu and Alun John in HONG KONG; Editing by Philip McClellan)  Continue reading the main story        We’re interested in your feedback on this page. Tell us what you think.                   What's Next    Loading...               Go to Home Page »   Site Index   The New York Times       Site Index Navigation    News    World    U.S.    Politics    N.Y.    Business    Tech    Science    Health    Sports    Education    Obituaries    Today's Paper    Corrections      Opinion    Today's Opinion    Op-Ed Columnists    Editorials    Op-Ed Contributors    Letters    Sunday Review    Video: Opinion      Arts    Today's Arts    Art & Design    Books    Dance    Movies    Music    N.Y.C. Events Guide    Television    Theater    Video: Arts      Living    Automobiles    Crossword    Food    Education    Fashion & Style    Health    Jobs    Magazine    N.Y.C. Events Guide    Real Estate    T Magazine    Travel    Weddings & Celebrations      Listings & More    Reader Center    Classifieds    Tools & Services    N.Y.C. Events Guide    Multimedia    Photography    Video    NYT Store    Times Journeys    Subscribe    Manage My Account    NYTCo      Subscribe   Subscribe    Home Delivery     Digital Subscriptions     Crossword      Email Newsletters    Alerts    Gift Subscriptions    Group Subscriptions    Education Rate      Mobile Applications    Replica Edition          Site Information Navigation    © 2018 The New York Times Company    Home  Search  Accessibility concerns? Email us at accessibility@nytimes.com . We would love to hear from you.  Contact Us  Work With Us  Advertise  Your Ad Choices  Privacy  Terms of Service  Terms of Sale     Site Information Navigation   Site Map  Help  Site Feedback  Subscriptions                     